ACAD9

Across TCGA pan-cancer cohorts, ACAD9 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ACAD9 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher ACAD9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ACAD9 expression acts as an unfavorable survival marker, although some lineages such as SKCM and LUSC show a favorable association.

CESC, ACC, and UCEC are the cancer types where ACAD9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	All	0.258	0.744	.005	12	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
BLCA	OS	Median	IV	0.193	0.598	.047	3	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	2	view →
LUSC	DFS	Median	All	0.895	0.386	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ACAD9–CESC (DFS)

Open the CESC breakdown →